Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 24-29

  Kelishadi, Roya ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Inflammation; Primary and Secondary Prevention; Primordial

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CHILDHOOD; DISEASE ASSOCIATION; DISEASE COURSE; EARLY LIFE STRESS; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NONHUMAN; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; THROMBOEMBOLISM;

EID: 78249274778     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010024     Document Type: Article

References (80)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
2. Rodríguez G, Mago N, Rosa F. Role of inflammation in atherogenesis. Invest Clin 2009; 50: 109-129.
3. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
4. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of Creactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127.
5. Steffens S, Mach F. Inflammation and atherosclerosis. Herz 2004; 29: 741-748.
6. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
7. Caligiuri G. Role of the immune response in atherosclerosis and acute coronary syndromes. Med Sci (Paris) 2004; 20:175-181.
8. Kunz J. Matrix metalloproteinases and atherogenesis in dependence of age. Gerontology 2007; 53: 63-73.
9. Yamada S, Wang KY, Tanimoto A, et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol 2008; 172: 1419-1429.
10. Choi ET, Collins ET, Marine LA, et al. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipo-protein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 1020-5.
11. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007; 5: 265-282.
12. Nobuhiko A, Suganuma E, Babaev VR, et al. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2143-8.
13. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009; 2009: 752406.
14. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 1982; 27: 83-111.
15. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immuno-histochemical localization of C-reactive protein binding sites in human aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int 1995; 45: 635-641.
16. Torzewski J, Torzewski M, Bowyer DE, et al. Creactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-1392.
17. Cermak J, Key N, Bach R, Balla J, Jacob HS, Vercellotti GM. Creactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
19. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
20. Linton MF, Fazio S. Cyclooxygenase products and atherosclerosis. Drug Discov Today Ther Strateg 2008; 5: 25-36.
21. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237-242.
22. Paris D, Town T, Humphrey J, Yokota K, Mullan M. Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a proinflammatory pathway. Biochem Biophys Res Commun 2000; 274: 553-558.
23. Hörkkö S, Binder CJ, Shaw PX, et al. Immunological responses to oxidized LDL. Free Radic Biol Med 2000; 28: 1771-1779.
24. Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing 2007; 4: 1.
25. Omoigui S. Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med Hypotheses 2005; 65: 559-569.
26. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996; 312: 1061-1065.
27. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167-2176.
28. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
29. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562-568.
30. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-294.
31. Tarantino G, Colicchio P, Conca P, et al. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond) 2009; 6: 6.
32. Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512.
33. Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006; 106: 291-297.
34. Momiyama Y, Kawaguchi A, Kajiwara I, et al. Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: The Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. Atherosclerosis 2009 Apr 17. [Epub ahead of print]
35. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta A. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis 2009; 19: 146-152.
36. Gasparyan AY, Mohammad-Hasani MR, Hassoun H, Darban H. Recent advances in cardiovascular medicine: the tenth Iranian congress on cardiovascular update. Arch Iran Med 2009; 12: 213-216.
37. MacKenzie KE, Wiltshire EJ, Peña AS, et al. Hs-CRP is associated with weight, BMI, and female sex but not with endothelial function in children with type 1 diabetes. Pediatr Diabetes 2009;10: 44-51.
38. Semiz S, Rota S, Ozdemir O, Ozdemir A, Kaptanoǧlu B. Are Creactive protein and homocysteine cardiovascular risk factors in obese children and adolescents? Pediatr Int 2008; 50: 419-423.
39. Ford ES. C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2003; 108: 1053-1058.
40. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
41. Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 2004; 112: 378-382.
42. Desideri G, De Simone M, Iughetti L, et al. Early activation of vascular endothelial cells and platelets in obese children. J Clin Endocrinol Metab 2005; 90: 3145-3152.
43. Kelishadi R, Sharifi M, Khosravi A, Adeli K. Relationship between C-reactive protein and atherosclerotic risk factors and oxidative stress markers among young persons 10-18 years old. Clin Chem 2007; 53: 456-464.
44. Kelishadi R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev 2007; 29: 62-76.
45. Kelishadi R, Ardalan G, Gheiratmand R, et al. CASPIAN Study Group. Association of physical activity and dietary behaviours in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bull World Health Organ 2007; 85: 19-26.
46. Kelishadi R, Gouya MM, Adeli K, et al. CASPIAN Study Group. Factors associated with the metabolic syndrome in a national sample of youths: CASPIAN Study. Nutr Metab Cardiovasc Dis 2008; 18: 461-470.
47. Roberts CK, Won D, Pruthi S, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006; 100: 1657-1665.
48. Kelishadi R, Hashemi M, Mohammadifard N, Asgary S, Khavarian N. Association of changes in oxidative and proinflammatory states with changes in vascular function after a lifestyle modification trial among obese children. Clin Chem 2008; 54: 147-153.
49. Kelishadi R, Cook SR, Motlagh ME, et al. Metabolically obese normal weight and phenotypically obese metabolically normal youths: the CASPIAN Study. J Am Diet Assoc 2008; 108: 82-90.
50. Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis 2009; 204: 538-543.
51. Kelishadi R, Hashemipour M, Sarrafzadegan N, et al. Effects of a lifestyle modification trial among phenotypically obese metabolically normal and phenotypically obese metabolically abnormal adolescents in comparison with phenotypically normal metabolically obese adolescents. J Mater Child Nutr 2009 (in press).
52. Juonala M, Viikari JS, Ronnemaa T, Taittonen L, Marniemi J, Raitakari OT. Childhood C-reactive protein in predicting CRP and carotid intima-media thickness in adulthood. The Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol 2006; 26: 1883-1888.
53. Mattsson N, Ronnemaa T, Juonala M, Viikari JS, Raitakari OT. Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study. Ann Med 2008; 40: 542-552.
54. Kelishadi R, Zadegan NS, Naderi GA, Asgary S, Bashardoust N. Atherosclerosis risk factors in children and adolescents with or without family history of premature coronary artery disease. Med Sci Monit 2002; 8: 425-429.
55. Kelishadi R, Nadery GA, Asgary S. Oxidized LDL metabolites with high family risk for premature cardiovascular disease. Indian J Pediatr 2002; 69: 755-759.
56. Magadle R, Merlon H, Weiner P, Mohammedi I, Robert D. Creactive protein levels and arterial abnormalities in the offspring of patients with premature myocardial infarction. Cardiology 2003; 100: 1-6.
57. Kelishadi R, Sabet B, Khosravi A. Anticardiolipin antibody of adolescents and age of myocardial infarction in parents. Med Sci Monit 2003; 9: 515-518.
58. Gaeta G, De Michele M, Cuomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343: 840-846.
59. Cuomo S, Guarini P, Gaeta G, et al. Increased carotid intima-media thickness in children-adolescents, and young adults with a parental history of premature myocardial infarction. Eur Heart J 2002; 23: 1345-1350.
60. Sabri MR, Kelishadi R. The thickness of the intimal and medial layers of the carotid arteries, and the index of left ventricular mass, in children of patients with premature coronary arterial disease. Cardiol Young 2007; 17: 609-616.
61. Kelishadi R, Sabri M, Motamedi N, Ramezani MA. Factor analysis of markers of inflammation and oxidation and echocardiographic findings in children with a positive family history of premature coronary heart disease. Pediatr Cardiol 2009; 30: 477-481.
62. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007; 16: 14-21.
63. Abramson JL, Hooper WC, Jones DP, et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005; 178: 115-121.
64. Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006; 26: 2476-2482.
65. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-1932.
66. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 106: 135-136.
67. Jacobs M, van Greevenbroek MM, van der Kallen CJ, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009 Apr 9. [Epub ahead of print]
68. Puddu P, Muscari A, Puddu GM, Cravero E, Giannoni C, Zoli M. The complexity of platelet metabolism and its contribution to atherothrombosis. Acta Cardiol 2009; 64: 157-165.
69. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
70. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.
71. Weber C, Schober A, Zernecke A. Chemokines key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24:1997-2008.
72. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dys-function and vascular disease. Biochem Pharmacol 2009 May 3. [Epub ahead of print]
73. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 612-616.
74. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardio-vascular prevention:implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
75. Wang L, Lu X, Li Y, Li H, Chen S, Gu D. Functional analysis of the C-reactive protein (CRP) gene-717A>G polymorphism associated with coronary heart disease. BMC Med Genet 2009; 10: 73.
76. Singh V, Tiwari RL, Dikshit M, Barthwal MK. Models to study atherosclerosis: a mechanistic insight. Curr Vasc Pharmacol 2009; 7: 75-109.
77. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302: 37-48.
78. Chen YC, Chen YD, et al. The HMG-CoA reductase gene and lipid and lipoprotein levels: the Multi-Ethnic study of atherosclerosis. Lipids 2009; 44: 733-743.
79. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003; 107: 1562-1566.
80. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009; 119: 1161-1175.